4.7 Article

Performance-enhancing drugs and the Olympics

Journal

JOURNAL OF INTERNAL MEDICINE
Volume 291, Issue 2, Pages 181-196

Publisher

WILEY
DOI: 10.1111/joim.13431

Keywords

antidoping; athletics; doping; medical history; Olympics; performance-enhancing drugs; toxicity; toxicology

Ask authors/readers for more resources

This article discusses the prohibition of performance-enhancing drugs (PEDs) in fair play rules and WADA's efforts to prevent PED use during the Olympic Games. It also reviews the characteristics and toxicities of different PED classes, emphasizing the importance for healthcare providers to be aware of PEDs and their risks, as they may encounter patients using PEDs.
The rules of fair play in sport generally prohibit the use of performance-enhancing drugs (PEDs). The World Anti-Doping Agency (WADA) oversees global antidoping regulations and testing for elite athletes participating in Olympic sports. Efforts to enforce antidoping policies are complicated by the diverse and evolving compounds and strategies employed by athletes to gain a competitive edge. Now between the uniquely proximate 2021 Tokyo and 2022 Beijing Olympic Games, we discuss WADA's efforts to prevent PED use during the modern Olympic Games. Then, we review the major PED classes with a focus on pathophysiology, complexities of antidoping testing, and relevant toxicities. Providers from diverse practice environments are likely to care for patients using PEDs for a variety of reasons and levels of sport; these providers should be aware of common PED classes and their risks.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available